Disclaimer - Putting Female Sexual Arousal Disorder On The Map: Expert Call with Dr. Sheryl Kingsberg

Disclaimer - Putting Female Sexual Arousal Disorder On The Map: Expert Call with Dr. Sheryl Kingsberg

DISCLAIMER – November 16, 2018

 

Topical sildenafil cream is an investigational agent in Phase 2 clinical development as a treatment for Female Sexual Arousal Disorder (FSAD). It has not yet been approved by the U.S. Food and Drug Administration as safe and effective to treat FSAD.  The following is a recording of The Putting Female Sexual Arousal on the Map conference call held on September 13, 2018 in which Dr. Yasmeen Rahimi and Dr. Sheryl A. Kingsberg participated. The recording includes opinions, beliefs, and estimates of the participants, related to, among other things, the potential safety and efficacy of topical sildenafil cream as a treatment for FSAD, future clinical trial design therefor, enrollment rates of future clinical trials, and commercial opportunities for topical sildenafil cream. Dr. Kingsberg, a clinical psychologist and recognized expert in female sexual disorders, provides consulting services to Daré Bioscience, Inc. from time to time. The opinions, beliefs, and estimates expressed in the recording are solely those of the participants, are as of the recording and do not necessarily represent those of Daré, its employees, or any agency or other organization.  Daré disclaims any responsibility or liability to any party for the accuracy or completeness of the content or for any damages arising out of use or nonuse of the content.

 

For information regarding Daré’s product candidates, including Sildenafil Cream, 3.6%, please visit https://www.darebioscience.com and carefully review the information provided in Daré’s most recent annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) and in its other SEC filings, including the risk factors in the Form 10-K and in subsequent quarterly reports on Form 10-Q, which describe known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, including those that relate to the Sildenafil Cream, 3.6% development program, to be materially different from any forward-looking statements in Daré’s SEC filings or from the opinions, beliefs, and estimates expressed in the recording.

 

Listen to call